Delivery Order SPE2DB22D9207-SPE2DB25FH4ZN
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency valued at $9,273.12 for the supply of Actemra Actpen 162 mg/0.9 ml injection pens. The award, issued on May 12, 2025, with an ultimate completion date of June 3, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's significant Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $5,313.27 by the Defense Logistics Agency (DLA) on August 19, 2025. The delivery order covers the supply of Actemra 400 mg/20 mL vials, a biologic medication used primarily for treating rheumatoid arthritis and other inflammatory conditions. This award was issued without a set-aside designation and is scheduled for...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,084.36 by the Defense Logistics Agency on September 16, 2025, for the supply of Actemra 400 mg/20 ml vials. This firm fixed-price delivery order is set to conclude by October 7, 2025, and will be fulfilled from the contractor's Park Ridge, Illinois location. The award was issued without a set-aside designation, leveraging the company's...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $2,923.36 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the provision of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a pharmaceutical product, with an ultimate completion date of April 25, 2024. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, SPE2DB, valued at up to $4,999,999 and held by DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,084.36 by the Defense Logistics Agency (DLA) on August 4, 2025, for the supply of Actemra 400 mg/20 ml vials. This firm fixed-price delivery order is not associated with a set-aside designation and carries an ultimate completion date of August 25, 2025. The award represents a single line item delivery under DMS Pharmaceutical Group's...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth up to $4,385.04 to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business located in Park Ridge, Illinois. The contract, which has no set-aside designation, is for the delivery of 4564299269 - Actemra Actpen 162 mg/0.9 ml 0.9ml syringes. This delivery order is part of a larger indefinite delivery contract (SPE2DB24FYW67) between DMS Pharmaceutical Group and DLA, valued at up to...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $2,192.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a biologic medication used to treat certain autoimmune conditions. This delivery order is issued under DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with DLA, which...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,884.92 contract is for the delivery of ACTEMRA 162 MG/0.9 ML syringes to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $9,273.12 to DMS Pharmaceutical Group Inc. for the supply of Actemra Actpen 162 mg/0.9 ml injections. The contract, issued on June 4, 2025, with an ultimate completion date of June 26, 2025, represents a standard procurement action with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,223.84 contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialized pharmaceutical product. The delivery order was issued under a $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, which enables the agency to procure...
- SPE2DB22D9207Indefinite Delivery Contract
- SPE2DB22D9207-SPE2DB25FH4ZNDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $2,318.25 by the Defense Logistics Agency (DLA) on May 2, 2025. The contract, which carries no set-aside designation, calls for delivery of Actemra 162 mg/0.9 ml syringes with an ultimate completion date of May 23, 2025. Actemra (tocilizumab) is a biologic immunosuppressant used primarily to treat rheumatoid arthritis and other inflammatory conditions. The place of performance is Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products, biologics, and medical supplies supporting Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, securing consistent contract awards from the DLA for specialized medications and medical consumables serving military health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 5/2/25 |